Vestal Point Capital LP Has $44.04 Million Stock Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Vestal Point Capital LP lifted its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 23.1% during the third quarter, HoldingsChannel reports. The firm owned 4,000,000 shares of the biotechnology company’s stock after purchasing an additional 750,000 shares during the period. Astria Therapeutics comprises 3.3% of Vestal Point Capital LP’s investment portfolio, making the stock its 8th biggest position. Vestal Point Capital LP owned about 0.07% of Astria Therapeutics worth $44,040,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. FMR LLC increased its position in Astria Therapeutics by 29.2% in the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after buying an additional 1,767,714 shares during the period. Vanguard Group Inc. increased its position in Astria Therapeutics by 23.4% during the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after acquiring an additional 480,184 shares during the period. Millennium Management LLC raised its stake in Astria Therapeutics by 13.5% during the 2nd quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock valued at $16,763,000 after purchasing an additional 218,518 shares during the last quarter. Affinity Asset Advisors LLC boosted its holdings in Astria Therapeutics by 15.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company’s stock valued at $8,878,000 after purchasing an additional 130,000 shares during the period. Finally, Nantahala Capital Management LLC acquired a new stake in Astria Therapeutics in the 2nd quarter worth $6,142,000. Institutional investors own 98.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Thursday, November 14th. Wedbush reissued an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a report on Tuesday, August 13th. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Finally, Oppenheimer lifted their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Stock Performance

Shares of NASDAQ ATXS opened at $10.50 on Friday. Astria Therapeutics, Inc. has a 52-week low of $4.50 and a 52-week high of $16.90. The business has a fifty day moving average of $11.18 and a two-hundred day moving average of $10.62. The stock has a market cap of $592.52 million, a PE ratio of -5.02 and a beta of 0.71.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.